Fortrea Holdings (FTRE) Income from Continuing Operations (2022 - 2026)
Fortrea Holdings (FTRE) posted Income from Continuing Operations of 23600000.0 for Q1 2026, up 27.38% on a QoQ basis from 32500000.0 in Q4 2025, and up 95.81% year-over-year from 12052658.32 in Q1 2025.
Fortrea Holdings (FTRE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Fortrea Holdings' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 23600000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 95.81% year-over-year to 23600000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 446900000.0 (up 40.78% YoY) and the FY2025 annual result came in at 986200000.0, down 263.24% from the prior year.
- Income from Continuing Operations was 23600000.0 for Q1 2026 at Fortrea Holdings, up from 32500000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 66400000.0 in Q2 2022 and bottomed at 562900000.0 in Q1 2025.
- A 5-year average of 74975000.0 and a median of 21050000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 1097.5% — and 2026, when it jumped 95.81%.
- Fortrea Holdings' Income from Continuing Operations stood at 13600000.0 in 2022, then plunged by 257.35% to 48600000.0 in 2023, then tumbled by 52.06% to 73900000.0 in 2024, then surged by 56.02% to 32500000.0 in 2025, then climbed by 27.38% to 23600000.0 in 2026.
- Business Quant data shows FTRE's Income from Continuing Operations at 23600000.0 in Q1 2026, 32500000.0 in Q4 2025, and 15900000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | -23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Jun 30, 2025 | -374.90 Mn |
| Mar 31, 2025 | -562.90 Mn |
| Dec 31, 2024 | -73.90 Mn |
| Sep 30, 2024 | -18.50 Mn |
| Jun 30, 2024 | -99.30 Mn |
| Mar 31, 2024 | -79.80 Mn |
| Dec 31, 2023 | -48.60 Mn |
| Sep 30, 2023 | -16.10 Mn |
| Jun 30, 2023 | 25.00 Mn |
| Mar 31, 2023 | 8.00 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | 60.60 Mn |
| Jun 30, 2022 | 66.40 Mn |